Gilead urged to sell long-acting HIV prevention drug directly to MSF
TL;DR
Doctors Without Borders (MSF) is pressing Gilead to directly sell lenacapavir, a two-a-year injectable PrEP for HIV prevention, to MSF for use in its humanitarian programs. Gilead has refused, directing MSF to obtain doses through the Global Fund, which has a limited supply, leaving many vulnerable people without access. MSF cites humanitarian need and calls for an urgent meeting by April 13 to decide pricing and delivery timelines.
- Gilead refuses to sell groundbreaking HIV prevention drug to MSF Doctors Without Borders
- Doctors Without Borders calls Gilead 'unconsionable' for refusing to sell HIV prevention drug to organization statnews.com
- [Press release] Médecins Sans Frontières: Gilead refuses to sell groundbreaking HIV prevention drug to MSF European AIDS Treatment Group
- Open letter to Gilead: Prevention should not be a privilege Doctors Without Borders
Want the full story? Read the original reporting
Read on Doctors Without Borders